Gas Sensing Capsule Could Uphold Gut Health
By HospiMedica International staff writers Posted on 22 Mar 2015 |
Image: Illustration of the swallowable gas sensing capsule (Photo courtesy of Nam Ha/ RMIT).
A novel ingestible capsule can measure the concentration of selected intestinal gases, opening new possibilities for diagnosis, treatment, and health analysis.
Developed by researchers at RMIT University (Melbourne, Australia) and Monash University (Melbourne, Australia), the capsule features bio-compatible cladding, a gas permeable membrane, gas sensor, electronic circuits such as sensor drivers, micro-controllers, wireless high-frequency transmission electronics, and a battery. Animal trials have demonstrated the effectiveness and safety of the capsules, which transmit data as they move through the gut to a handheld device such as a mobile phone, before passing out of the body.
Currently, doctors rely on indirect measurements, such as breath and fecal analysis, to gauge which gases are in the intestine. But an ingested sensor could directly analyze the gases released when bacteria ferment undigested food in the gut, such as carbon dioxide (CO2), hydrogen, methane, oxygen, and hydrogen sulphide. Supporting apps could have libraries that compare fractional gas concentrations in various states, so that the relative changes would indicate certain diseases or intestinal conditions. The study describing the capsule was published on March 12, 2015, in Trends in Biotechnology.
“A gas-sensing pill could give you a real-time glimpse into what’s going on in your gut; as the gases permeate the capsule, the sensors produce signals and digitize the data, then send it to an app,” said senior author Prof. Kourosh Kalantar-Zadeh, PHD, of RMIT. “If some organic compound like butyrate goes up, that means something is happening to the wall of the stomach, and the thing that is happening is generally not good, has to be detected, and should be addressed very quickly.”
“We know gut microorganisms produce gases as a by-product of their metabolism, but we understand very little about how that affects our health,” added Prof. Kalantar-Zadeh. “Being able to accurately measure intestinal gases could accelerate our knowledge about how specific gut microorganisms contribute to gastrointestinal disorders and food intake efficiency, enabling the development of new diagnostic techniques and treatments.”
Intestinal gases have been linked to colon cancer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), and could potentially be used as key biomarkers for assessing overall health.
Related Links:
RMIT University
Monash University
Developed by researchers at RMIT University (Melbourne, Australia) and Monash University (Melbourne, Australia), the capsule features bio-compatible cladding, a gas permeable membrane, gas sensor, electronic circuits such as sensor drivers, micro-controllers, wireless high-frequency transmission electronics, and a battery. Animal trials have demonstrated the effectiveness and safety of the capsules, which transmit data as they move through the gut to a handheld device such as a mobile phone, before passing out of the body.
Currently, doctors rely on indirect measurements, such as breath and fecal analysis, to gauge which gases are in the intestine. But an ingested sensor could directly analyze the gases released when bacteria ferment undigested food in the gut, such as carbon dioxide (CO2), hydrogen, methane, oxygen, and hydrogen sulphide. Supporting apps could have libraries that compare fractional gas concentrations in various states, so that the relative changes would indicate certain diseases or intestinal conditions. The study describing the capsule was published on March 12, 2015, in Trends in Biotechnology.
“A gas-sensing pill could give you a real-time glimpse into what’s going on in your gut; as the gases permeate the capsule, the sensors produce signals and digitize the data, then send it to an app,” said senior author Prof. Kourosh Kalantar-Zadeh, PHD, of RMIT. “If some organic compound like butyrate goes up, that means something is happening to the wall of the stomach, and the thing that is happening is generally not good, has to be detected, and should be addressed very quickly.”
“We know gut microorganisms produce gases as a by-product of their metabolism, but we understand very little about how that affects our health,” added Prof. Kalantar-Zadeh. “Being able to accurately measure intestinal gases could accelerate our knowledge about how specific gut microorganisms contribute to gastrointestinal disorders and food intake efficiency, enabling the development of new diagnostic techniques and treatments.”
Intestinal gases have been linked to colon cancer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), and could potentially be used as key biomarkers for assessing overall health.
Related Links:
RMIT University
Monash University
Latest Critical Care News
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease